Biologic Therapies Improve Work Outcomes in Spondyloarthritis

By Jack Cush, MD | 14 September 2018

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

The BSRBR-AS registry analyzed 577 participants who were employed; 28% were started on biological therapy .

After 12-months of follow-up, those receiving biologic therapy had significantly greater improvements (relative to non-biological therapy) in presenteeism, overall work impairment, and overall activity impairment; however there was no difference in absenteeism.

There is consistent evidence that treatment with biological therapy improves these work and activity measures.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

By Jack Cush, MD | 12 Feb 2019

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

[...]

Biologics in Psoriasis Tied to Better Heart Health

By MedPage Today | 06 Feb 2019

Biologic therapy for severe psoriasis was associated with better plaque morphology and less non-calcified coronary plaque, according to a prospective, observational study.

[...]

Low IBD Risk with Secukinumab

By MedPage Today | 30 Jan 2019

The interleukin-23 (IL-23)/IL-17 axis plays an important role in inflammation and infection. Some of these chronic immune-mediated inflammatory disorders include PsO, PsA, AS, and IBD. Patients with PsO, PsA, and AS have up to a four-fold risk of developing IBD versus the general population. One study also supported the role for gut inflammation in spondyloarthropathy.

[...]

Ixekizumab and Complete Resolution of Enthesitis and Dactylitis

By Jack Cush, MD | 30 Jan 2019

IL-17 inhibitors have proven to be effective in psoriatic arthritis. Analyses of ixekizumab-treated PsA patients with enthesitis or dactylitis shows this approach to yield significant improvements in enthesitis and dactylitis.

[...]

Obesity Needs to be Treated in Psoriatic Arthritis

By MedPage Today | 24 Jan 2019

Obese patients with psoriatic arthritis (PsA) who followed a short-term, very low-energy diet showed improvements in multiple aspects of disease activity, a prospective study found.

Over a period of 6 months, patients on the restrictive diet (640 kcal/day) lost a median of 18.7 kg (41.2 lbs), which represented 18.6% of their weight, according to Eva Klingberg, MD, PhD, of the University of Gothenburg in Sweden, and colleagues.

[...]

You are here